Cordis Corporation

169 articles about Cordis Corporation

• Cordis Announces Scott Drake as Chief Executive Officer

  11/6/2023

  Cordis announced that its Board of Directors has appointed Scott Drake as Chief Executive Officer effective immediately.

• Cordis issues statement on the CMS announcement to expand coverage of carotid stenting

  10/16/2023

  Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, strongly supports the decision made by the Centers for Medicare & Medicaid Services to expand coverage of carotid artery stenting cms.gov.

• Cordis Announces the Completed Acquisition of MedAlliance

  10/2/2023

  Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, announced that it has completed the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology.

• Cordis Names Bryan Loo President of Asia-Pacific Region

  7/8/2022

  Cordis, a global leader in cardiovascular technologies, announced that Bryan Loo will assume the role of President of the Asia-Pacific region effective July 18, 2022.

• Endovascular Engineering Secures $15 Million Series A1 Financing For Venous Thrombectomy Solutions

  4/5/2022

  Endovascular Engineering, a privately-held developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis and Pulmonary Embolism, announced the closing of a $15 million Series A1 financing.

• Cordis Continues to Expand Interventional Cardiology Portfolio with Radial Offering

  5/14/2019

  Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach for interventional cardiology procedures.

• 

  FDA Action Alert: Cordis and PneumRx

  6/11/2018

  Although there are no U.S. Food and Drug Administration (FDA) approvals expected for this week, there are two Adcom meetings. Advisory Committees are used by the agency to obtain independent expert advice on scientific, technical, and policy matters.
• 

  Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

  11/30/2017

  Cordis today announced FDA approval of the EluNIR drug-eluting stent for the treatment of patients with narrowing or blockages to their coronary arteries

• Cardinal Health's Cordis Recalls Precise Pro RX Carotid Stent Over Separation Issues

  6/1/2016

• Cordis Announces Return to the Drug-Eluting Stent Market

  5/12/2016

• Johnson & Johnson Announces Completion Of Cordis Divestiture To Cardinal Health

  10/5/2015

• Cardinal Health Completes Acquisition Of Cordis

  10/5/2015

• Cordis Expands Crossing Portfolio For The Treatment Of Chronic Total Occlusions

  6/8/2015

• Johnson & Johnson Finally Agrees to Sell Cordis to Cardinal Health

  5/29/2015

• Cardinal Health Binding Offer To Acquire Cordis Accepted

  5/28/2015

• Cardinal Health Ponies Up $1.944 Billion Cash for Johnson & Johnson's Cordis

  3/3/2015

• Cardinal Health, Inc. Revealed as Top Suitor for Johnson & Johnson's $2 Billion Cordis Corporation Unit

  2/23/2015

• Cordis Corporation Leads With Strong Podium Presence At VEITH 2014 With First-Ever Presentation Of Three-Year INCRAFT System Data

  11/19/2014

• Cordis Corporation Launches INCRAFT® AAA Stent Graft System For Treatment Of Abdominal Aortic Aneurysms (AAA)

  9/10/2014

• Johnson & Johnson Seeks Buyer For Struggling Medical Device Unit Cordis Corporation; Deal Could Fetch Up To $2 Billion

  8/29/2014